Evidence  ||| S:0 E:9 ||| NN
for  ||| S:9 E:13 ||| IN
S-adenosyl-L-methionine  ||| S:13 E:37 ||| NNP
( ||| S:37 E:38 ||| -LRB-
SAM-e ||| S:38 E:43 ||| NNP
)  ||| S:43 E:45 ||| -RRB-
for  ||| S:45 E:49 ||| IN
the  ||| S:49 E:53 ||| DT
treatment  ||| S:53 E:63 ||| NN
of  ||| S:63 E:66 ||| IN
major  ||| S:66 E:72 ||| JJ
depressive  ||| S:72 E:83 ||| JJ
disorder  ||| S:83 E:92 ||| NN
Despite  ||| S:92 E:100 ||| IN
the  ||| S:100 E:104 ||| DT
increasingly  ||| S:104 E:117 ||| RB
large  ||| S:117 E:123 ||| JJ
array  ||| S:123 E:129 ||| NN
of  ||| S:129 E:132 ||| IN
antidepressants  ||| S:132 E:148 ||| JJ
available  ||| S:148 E:158 ||| JJ
to  ||| S:158 E:161 ||| TO
treat  ||| S:161 E:167 ||| VB
major  ||| S:167 E:173 ||| JJ
depressive  ||| S:173 E:184 ||| JJ
disorder ||| S:184 E:192 ||| NN
,  ||| S:192 E:194 ||| ,
patients  ||| S:194 E:203 ||| NNS
continue  ||| S:203 E:212 ||| VBP
to  ||| S:212 E:215 ||| TO
experience  ||| S:215 E:226 ||| VB
relatively  ||| S:226 E:237 ||| RB
modest  ||| S:237 E:244 ||| JJ
response  ||| S:244 E:253 ||| NN
and  ||| S:253 E:257 ||| CC
remission  ||| S:257 E:267 ||| JJ
rates ||| S:267 E:272 ||| NNS
.  ||| S:272 E:274 ||| .
In  ||| S:274 E:277 ||| IN
addition ||| S:277 E:285 ||| NN
,  ||| S:285 E:287 ||| ,
patients  ||| S:287 E:296 ||| NNS
may  ||| S:296 E:300 ||| MD
experience  ||| S:300 E:311 ||| VB
adverse  ||| S:311 E:319 ||| JJ
side  ||| S:319 E:324 ||| NN
effects  ||| S:324 E:332 ||| NNS
from  ||| S:332 E:337 ||| IN
pharmacotherapy  ||| S:337 E:353 ||| NNS
that  ||| S:353 E:358 ||| WDT
not  ||| S:358 E:362 ||| RB
only  ||| S:362 E:367 ||| RB
hinder  ||| S:367 E:374 ||| VB
treatment  ||| S:374 E:384 ||| NN
compliance  ||| S:384 E:395 ||| NN
and  ||| S:395 E:399 ||| CC
adherence  ||| S:399 E:409 ||| NNS
but ||| S:409 E:412 ||| CC
,  ||| S:412 E:414 ||| ,
in  ||| S:414 E:417 ||| IN
some  ||| S:417 E:422 ||| DT
cases ||| S:422 E:427 ||| NNS
,  ||| S:427 E:429 ||| ,
may  ||| S:429 E:433 ||| MD
also  ||| S:433 E:438 ||| RB
contribute  ||| S:438 E:449 ||| VB
to  ||| S:449 E:452 ||| TO
increased  ||| S:452 E:462 ||| JJ
disability ||| S:462 E:472 ||| NN
,  ||| S:472 E:474 ||| ,
patient  ||| S:474 E:482 ||| JJ
suffering ||| S:482 E:491 ||| NN
,  ||| S:491 E:493 ||| ,
morbidity ||| S:493 E:502 ||| NN
,  ||| S:502 E:504 ||| ,
and  ||| S:504 E:508 ||| CC
mortality ||| S:508 E:517 ||| NN
.  ||| S:517 E:519 ||| .
In  ||| S:519 E:522 ||| IN
order  ||| S:522 E:528 ||| NN
to  ||| S:528 E:531 ||| TO
enhance  ||| S:531 E:539 ||| VB
treatment  ||| S:539 E:549 ||| NN
efficacy  ||| S:549 E:558 ||| NNS
and  ||| S:558 E:562 ||| CC
tolerability ||| S:562 E:574 ||| NN
,  ||| S:574 E:576 ||| ,
patients  ||| S:576 E:585 ||| NNS
and  ||| S:585 E:589 ||| CC
clinicians  ||| S:589 E:600 ||| NNS
have  ||| S:600 E:605 ||| VBP
become  ||| S:605 E:612 ||| VBN
increasingly  ||| S:612 E:625 ||| RB
interested  ||| S:625 E:636 ||| VBN
in  ||| S:636 E:639 ||| IN
nonpharmaceutical  ||| S:639 E:657 ||| JJ
supplements  ||| S:657 E:669 ||| NN
for  ||| S:669 E:673 ||| IN
treating  ||| S:673 E:682 ||| VBG
depression ||| S:682 E:692 ||| NN
.  ||| S:692 E:694 ||| .
One  ||| S:694 E:698 ||| CD
of  ||| S:698 E:701 ||| IN
the  ||| S:701 E:705 ||| DT
best-studied  ||| S:705 E:718 ||| JJ
of  ||| S:718 E:721 ||| IN
these  ||| S:721 E:727 ||| DT
supplements  ||| S:727 E:739 ||| NN
is  ||| S:739 E:742 ||| VBZ
S-adenosyl-L-methionine  ||| S:742 E:766 ||| JJ
( ||| S:766 E:767 ||| -LRB-
SAM-e ||| S:767 E:772 ||| NNP
) ||| S:772 E:773 ||| -RRB-
,  ||| S:773 E:775 ||| ,
a  ||| S:775 E:777 ||| DT
naturally  ||| S:777 E:787 ||| RB
occurring  ||| S:787 E:797 ||| VBG
molecule  ||| S:797 E:806 ||| NN
present  ||| S:806 E:814 ||| NN
in  ||| S:814 E:817 ||| IN
all  ||| S:817 E:821 ||| DT
living  ||| S:821 E:828 ||| NN
cells  ||| S:828 E:834 ||| NNS
and  ||| S:834 E:838 ||| CC
a  ||| S:838 E:840 ||| DT
major  ||| S:840 E:846 ||| JJ
methyl  ||| S:846 E:853 ||| JJ
group  ||| S:853 E:859 ||| NN
donor  ||| S:859 E:865 ||| NN
in  ||| S:865 E:868 ||| IN
the  ||| S:868 E:872 ||| DT
human  ||| S:872 E:878 ||| JJ
body ||| S:878 E:882 ||| NN
.  ||| S:882 E:884 ||| .
Controlled  ||| S:884 E:895 ||| JJ
trials  ||| S:895 E:902 ||| NNS
have  ||| S:902 E:907 ||| VBP
found  ||| S:907 E:913 ||| VBN
SAM-e  ||| S:913 E:919 ||| JJ
to  ||| S:919 E:922 ||| TO
be  ||| S:922 E:925 ||| VB
more  ||| S:925 E:930 ||| JJR
efficacious  ||| S:930 E:942 ||| NN
than  ||| S:942 E:947 ||| IN
placebo  ||| S:947 E:955 ||| NN
and  ||| S:955 E:959 ||| CC
equal  ||| S:959 E:965 ||| JJ
in  ||| S:965 E:968 ||| IN
efficacy  ||| S:968 E:977 ||| VBG
to  ||| S:977 E:980 ||| TO
the  ||| S:980 E:984 ||| DT
tricyclic  ||| S:984 E:994 ||| JJ
antidepressants  ||| S:994 E:1010 ||| NN
for  ||| S:1010 E:1014 ||| IN
treating  ||| S:1014 E:1023 ||| VBG
major  ||| S:1023 E:1029 ||| JJ
depressive  ||| S:1029 E:1040 ||| JJ
disorder  ||| S:1040 E:1049 ||| NN
( ||| S:1049 E:1050 ||| -LRB-
MDD ||| S:1050 E:1053 ||| NNP
)  ||| S:1053 E:1055 ||| -RRB-
when  ||| S:1055 E:1060 ||| WRB
administered  ||| S:1060 E:1073 ||| JJ
parenterally  ||| S:1073 E:1086 ||| NNS
( ||| S:1086 E:1087 ||| -LRB-
either  ||| S:1087 E:1094 ||| DT
intravenously  ||| S:1094 E:1108 ||| NN
or  ||| S:1108 E:1111 ||| CC
intramuscularly ||| S:1111 E:1126 ||| CD
) ||| S:1126 E:1127 ||| -RRB-
.  ||| S:1127 E:1129 ||| .
Less  ||| S:1129 E:1134 ||| JJR
evidence  ||| S:1134 E:1143 ||| NN
supports  ||| S:1143 E:1152 ||| VBZ
the  ||| S:1152 E:1156 ||| DT
use  ||| S:1156 E:1160 ||| NN
of  ||| S:1160 E:1163 ||| IN
oral  ||| S:1163 E:1168 ||| JJ
SAM-e ||| S:1168 E:1173 ||| NN
,  ||| S:1173 E:1175 ||| ,
although  ||| S:1175 E:1184 ||| IN
some  ||| S:1184 E:1189 ||| DT
trials  ||| S:1189 E:1196 ||| NNS
have  ||| S:1196 E:1201 ||| VBP
demonstrated  ||| S:1201 E:1214 ||| VBN
its  ||| S:1214 E:1218 ||| PRP$
efficacy  ||| S:1218 E:1227 ||| NN
as  ||| S:1227 E:1230 ||| IN
well ||| S:1230 E:1234 ||| RB
.  ||| S:1234 E:1236 ||| .
In  ||| S:1236 E:1239 ||| IN
addition ||| S:1239 E:1247 ||| NN
,  ||| S:1247 E:1249 ||| ,
there  ||| S:1249 E:1255 ||| EX
is  ||| S:1255 E:1258 ||| VBZ
a  ||| S:1258 E:1260 ||| DT
paucity  ||| S:1260 E:1268 ||| NN
of  ||| S:1268 E:1271 ||| IN
evidence  ||| S:1271 E:1280 ||| NN
examining  ||| S:1280 E:1290 ||| VBG
whether  ||| S:1290 E:1298 ||| IN
oral  ||| S:1298 E:1303 ||| JJ
forms  ||| S:1303 E:1309 ||| NNS
of  ||| S:1309 E:1312 ||| IN
SAM-e  ||| S:1312 E:1318 ||| NNP
can  ||| S:1318 E:1322 ||| MD
be  ||| S:1322 E:1325 ||| VB
safe ||| S:1325 E:1329 ||| JJ
,  ||| S:1329 E:1331 ||| ,
well  ||| S:1331 E:1336 ||| RB
tolerated ||| S:1336 E:1345 ||| JJ
,  ||| S:1345 E:1347 ||| ,
and  ||| S:1347 E:1351 ||| CC
efficacious  ||| S:1351 E:1363 ||| NN
when  ||| S:1363 E:1368 ||| WRB
used  ||| S:1368 E:1373 ||| VBN
as  ||| S:1373 E:1376 ||| IN
adjunctive  ||| S:1376 E:1387 ||| JJ
treatment  ||| S:1387 E:1397 ||| NN
for  ||| S:1397 E:1401 ||| IN
antidepressant  ||| S:1401 E:1416 ||| JJ
nonresponders  ||| S:1416 E:1430 ||| NN
with  ||| S:1430 E:1435 ||| IN
MDD ||| S:1435 E:1438 ||| NNP
.  ||| S:1438 E:1440 ||| .
Although  ||| S:1440 E:1449 ||| IN
preliminary  ||| S:1449 E:1461 ||| JJ
data  ||| S:1461 E:1466 ||| NNS
suggest  ||| S:1466 E:1474 ||| VBP
SAM-e  ||| S:1474 E:1480 ||| NNS
may  ||| S:1480 E:1484 ||| MD
be  ||| S:1484 E:1487 ||| VB
useful  ||| S:1487 E:1494 ||| JJ
as  ||| S:1494 E:1497 ||| IN
an  ||| S:1497 E:1500 ||| DT
adjunctive  ||| S:1500 E:1511 ||| JJ
therapy  ||| S:1511 E:1519 ||| NN
to  ||| S:1519 E:1522 ||| TO
antidepressants ||| S:1522 E:1537 ||| VB
,  ||| S:1537 E:1539 ||| ,
controlled  ||| S:1539 E:1550 ||| VBN
studies  ||| S:1550 E:1558 ||| NNS
are  ||| S:1558 E:1562 ||| VBP
needed  ||| S:1562 E:1569 ||| VBN
to  ||| S:1569 E:1572 ||| TO
confirm  ||| S:1572 E:1580 ||| VB
or  ||| S:1580 E:1583 ||| CC
refute  ||| S:1583 E:1590 ||| VB
these  ||| S:1590 E:1596 ||| DT
preliminary  ||| S:1596 E:1608 ||| JJ
findings ||| S:1608 E:1616 ||| NNS
.  ||| S:1616 E:1618 ||| .
